Research programme: cell-penetrating antibody therapeutics - LA Cell

Drug Profile

Research programme: cell-penetrating antibody therapeutics - LA Cell

Alternative Names: Intracellular Targeting Antibodies -LA Cell; iTAbs; KRASG12D iTAb; Mutant KRAS iTAb; STAT3 iTAb

Latest Information Update: 20 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LA Cell
  • Developer City of Hope National Medical Center; LA Cell
  • Class Monoclonal antibodies
  • Mechanism of Action Protein modulators; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Apr 2018 Sorrento Therapeutics has patents pending for the intracellular targeting antibody (iTAb) technology (LA Cell) for targeting intracellular targets
  • 22 Mar 2017 Preclinical trials in Cancer in USA (IV)
  • 29 Sep 2015 LA Cell in-licenses a technology to develop cell-penetrating antibody therapeutics from City of Hope National Medical Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top